[How should one advance the current therapeutic strategies and objectives?].
Jullien
Denis
D
Service de Dermatologie, Hôpital Edouard Herriot, Lyon, France. denis.jullien@chu-lyon.fr
Boulinguez
Serge
S
D001691:Biological Therapy / Q000009:adverse effects; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D015897:Comorbidity; D003879:Dermatologic Agents / Q000627:therapeutic use; D005260:Female; D006040:Goals; D006801:Humans; D008017:Life Expectancy; D008297:Male; D024821:Metabolic Syndrome / Q000453:epidemiology; D009260:Nail Diseases / Q000453:epidemiology / Q000473:pathology; D011565:Psoriasis / Q000188:drug therapy / Q000453:epidemiology / Q000473:pathology / Q000628:therapy*; D012042:Registries; D018570:Risk Assessment; D006113:United Kingdom / Q000453:epidemiology
D003879:Dermatologic Agents